Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments

被引：90

作者：

Marchetti, Claudia ^{[1
]}

De Felice, Francesca ^{[2
,3
]}

Romito, Alessia ^{[4
]}

Iacobelli, Valentina ^{[1
,5
]}

Sassu, Carolina Maria ^{[6
]}

Corrado, Giacomo ^{[1
]}

Ricci, Caterina ^{[1
]}

Scambia, Giovanni ^{[1
,5
]}

Fagotti, Anna ^{[1
,5
]}

机构：

[1] Fdn Policlin Univ A Gemelli IRCCS, Div Gynecol Oncol, Rome, Italy

[2] Policlin Umberto 1, Div Radiotherapy & Oncol, Rome, Italy

[3] Univ Roma La Sapienza, Rome, Italy

[4] Mater Olbia Hosp, Gynecol & Breast Care Ctr, Olbia, Italy

[5] Univ Cattolica Sacro Cuore, Dept Woman & Child Hlth Sci, Rome, Italy

[6] Sapienza Univ Rome, Polyclin Umberto I, Dept Maternal & Child Hlth & Urol Sci, Rome, Italy

来源：

SEMINARS IN CANCER BIOLOGY | 2021年 / 77卷

关键词：

Ovarian cancer; Platinum resistance; Predictive biomarkers; Innovative drugs; PHASE-II TRIAL; MITOCHONDRIAL TRANSCRIPTION FACTOR; FALLOPIAN-TUBE CANCER; PLATINUM-BASED CHEMOTHERAPY; PRIMARY PERITONEAL CANCER; GRADE SEROUS CARCINOMA; FOLATE RECEPTOR-ALPHA; DNA-DAMAGE RESPONSE; RECURRENT OVARIAN; POOR-PROGNOSIS;

D O I：

10.1016/j.semcancer.2021.08.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer (OC) remains a fatal malignancy because most patients experience recurrent disease, which is resistant to chemotherapy. The outcomes for patients with platinum-resistant OC are poor, response rates to further chemotherapy are low and median survival is lower than 12 months. The complexity of platinum-resistant OC, which comprises a heterogeneous spectrum of diseases, is indeed far from being completely un-derstood. Therefore, comprehending tumors' biological behaviour to identify reliable biomarkers, which may predict responses to therapies, is a demanding challenge to improve OC management. In the age of precision medicine, efforts to overcome platinum resistance in OC represent a dynamic and vast field in which innovative drugs and clinical trials rapidly develop. This review will present the exceptional biochemical environment implicated in OC and highlights mechanisms of chemoresistance. Furthermore, innovative molecules and new therapeutic opportunities are presented, along with currently available therapies and ongoing clinical trials.

引用

页码：144 / 166

页数：23

共 242 条

[1]

Abouelfadl H, 2021, SEMIN CANCER BIOL, DOI [10.1016/j.semcancer.2020.12.024.S1044-579X(21)00003-1, DOI 10.1016/J.SEMCANCER.2020.12.024.S1044-579X(21)00003-1]

[2] Phase I study combining olaparib and tremelimumab for the treatment of women with BRCA-deficient recurrent ovarian cancer. [J].

Adams, Sarah Foster ;

Rixe, Olivier ;

Lee, Ji-Hyun ;

McCance, Dennis J. ;

Westgate, Sheri ;

Eberhardt, Steven C. ;

Rutledge, Teresa ;

Muller, Carolyn .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[3] Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas [J].

Anglesio, Michael S. ;

Kommoss, Stefan ;

Tolcher, Mary C. ;

Clarke, Blaise ;

Galletta, Laura ;

Porter, Henry ;

Damaraju, Sambasivarao ;

Fereday, Sian ;

Winterhoff, Boris J. ;

Kalloger, Steve E. ;

Senz, Janine ;

Yang, Winnie ;

Steed, Helen ;

Allo, Ghassan ;

Ferguson, Sarah ;

Shaw, Patricia ;

Teoman, Attila ;

Garcia, Joaquin J. ;

Schoolmeester, John K. ;

Bakkum-Gamez, Jamie ;

Tinker, Anna V. ;

Bowtell, David D. ;

Huntsman, David G. ;

Gilks, C. Blake ;

McAlpine, Jessica N. .

JOURNAL OF PATHOLOGY, 2013, 229 (01) :111-120

[4]

[Anonymous], 2014, J CLIN ONCOL, V32, P4025

[5]

Arnold Y., J CLIN ONCOL, V29, P2197

[6] Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study [J].

Banerjee, S. ;

Oza, A. M. ;

Birrer, M. J. ;

Hamilton, E. P. ;

Hasan, J. ;

Leary, A. ;

Moore, K. N. ;

Mackowiak-Matejczyk, B. ;

Pikiel, J. ;

Ray-Coquard, I. ;

Trask, P. ;

Lin, K. ;

Schuth, E. ;

Vaze, A. ;

Choi, Y. ;

Marsters, J. C. ;

Maslyar, D. J. ;

Lemahieu, V. ;

Wang, Y. ;

Humke, E. W. ;

Liu, J. F. .

ANNALS OF ONCOLOGY, 2018, 29 (04) :917-923

[7] Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer [J].

Bapat, SA ;

Mali, AM ;

Koppikar, CB ;

Kurrey, NK .

CANCER RESEARCH, 2005, 65 (08) :3025-3029

[8] ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance [J].

Begicevic, Romana-Rea ;

Falasca, Marco .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (11)

[9] Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study [J].

Behbakht, Kian ;

Sill, Michael W. ;

Darcy, Kathleen M. ;

Rubin, Stephen C. ;

Mannel, Robert S. ;

Waggoner, Steven ;

Schilder, Russell J. ;

Cai, Kathy Q. ;

Godwin, Andrew K. ;

Alpaugh, R. Katherine .

GYNECOLOGIC ONCOLOGY, 2011, 123 (01) :19-26

[10] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

← 1 2 3 4 5 6 7 8 9 10 →